|
Mr. McWilliams has over 30 years of experience building public and private biopharmaceutical / healthcare companies. Since 1992 as an investor and CEO Mr. McWilliams has led several companies at key points of their development. Most notably he was President CEO and Director of Encysive Pharmaceuticals (ENCY). At Encysive he raised $250 million in public financings and corporate partnerships. Under his leadership the company developed licensed and received FDA approval in 2000 for an anticoagulant Argatroban which is currently marketed by Glaxo Smith Kline. From 1980 to 1992 Mr. McWilliams was President and CEO of several healthcare companies. From 1972 to 1980 he was an executive at Abbott Laboratories rising up to General Manager of South Africa. Previously he was a management consultant at McKinsey & Co. Mr. McWilliams received an MBA in Finance from the University of Chicago and B.A. in Chemistry Phi Beta Kappa from Washington and Jefferson College. Mr. McWilliams has been a Director of Texas Health Plan GenTrans Technology Zonagen (ZONA) Encysive Pharmaceuticals (ENCY) DIFCO Laboratories and Structural Bioinformatics. He is currently a Director of Fairway Medical Technologies Houston Technology Center and Texas Healthcare and Bioscience Institute. | 